{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:28:42Z","timestamp":1771036122720,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Daiichi Sankyo Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s12325-019-01121-2","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T17:08:23Z","timestamp":1573232903000},"page":"253-264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4667-6092","authenticated-orcid":false,"given":"Akifumi","family":"Kurata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Nakatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"key":"1121_CR1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1161\/CIRCHEARTFAILURE.108.821199","volume":"2","author":"S Bansal","year":"2009","unstructured":"Bansal S, Lindenfeld J, Schrier RW. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail. 2009;2:370\u20136.","journal-title":"Circ Heart Fail"},{"key":"1121_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1001\/jamacardio.2016.1878","volume":"1","author":"DM Flatt","year":"2016","unstructured":"Flatt DM, Brown MC, Mizeracki AM, King BJ, Weber KT. Mineralocorticoid receptor antagonists in the management of heart failure and resistant hypertension: a review. JAMA Cardiol. 2016;1:607\u201312.","journal-title":"JAMA Cardiol"},{"key":"1121_CR3","doi-asserted-by":"crossref","unstructured":"The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol. 1996; 78:902\u20137.","DOI":"10.1016\/S0002-9149(96)00465-1"},{"key":"1121_CR4","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309\u201321.","journal-title":"N Engl J Med"},{"key":"1121_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11\u201321.","journal-title":"N Engl J Med"},{"key":"1121_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","volume":"200","author":"M Lainscak","year":"2015","unstructured":"Lainscak M, Pelliccia F, Rosano G, et al. Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int J Cardiol. 2015;200:25\u20139.","journal-title":"Int J Cardiol"},{"key":"1121_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","volume":"10","author":"DA Sica","year":"2005","unstructured":"Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev. 2005;10:23\u20139.","journal-title":"Heart Fail Rev"},{"key":"1121_CR8","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","volume":"761","author":"K Arai","year":"2015","unstructured":"Arai K, Homma T, Morikawa Y, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol. 2015;761:226\u201334.","journal-title":"Eur J Pharmacol"},{"key":"1121_CR9","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1111\/bcp.13616","volume":"84","author":"M Kato","year":"2018","unstructured":"Kato M, Furuie H, Shimizu T, Miyazaki A, Kobayashi F, Ishizuka H. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects. Br J Clin Pharmacol. 2018;84:1821\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"1121_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00956-z","author":"A Kurata","year":"2019","unstructured":"Kurata A, Furuie H, Ishizuka T, et al. Absolute bioavailability of esaxerenone and food effects on its pharmacokinetics after a single oral dose in healthy Japanese subjects. Adv Ther. 2019. \nhttps:\/\/doi.org\/10.1007\/s12325-019-00956-z\n\n.","journal-title":"Adv Ther"},{"key":"1121_CR11","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3748\/wjg.v22.i3.1260","volume":"22","author":"P Palatini","year":"2016","unstructured":"Palatini P, De Martin S. Pharmacokinetic drug interactions in liver disease: an update. World J Gastroenterol. 2016;22:1260\u201378.","journal-title":"World J Gastroenterol"},{"key":"1121_CR12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64:1147\u201361.","journal-title":"Eur J Clin Pharmacol"},{"key":"1121_CR13","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1161\/01.CIR.0000071081.35693.9A","volume":"107","author":"NJ Brown","year":"2003","unstructured":"Brown NJ. Eplerenone: cardiovascular protection. Circulation. 2003;107:2512\u20138.","journal-title":"Circulation"},{"key":"1121_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/BF00606407","volume":"11","author":"L Jackson","year":"1977","unstructured":"Jackson L, Branch R, Levine D, Ramsay L. Elimination of canrenone in congestive heart failure and chronic liver disease. Eur J Clin Pharmacol. 1977;11:177\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"1121_CR15","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/0016-5085(92)91730-R","volume":"102","author":"I Sungaila","year":"1992","unstructured":"Sungaila I, Bartle WR, Walker SE, et al. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology. 1992;102:1680\u20135.","journal-title":"Gastroenterology"},{"key":"1121_CR16","unstructured":"INSPRA\u00ae (eplerenone) US prescribing information. \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021437s006lbl.pdf\n\n. Accessed 16 Aug 2018."},{"key":"1121_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1124\/dmd.118.084897","volume":"47","author":"M Yamada","year":"2019","unstructured":"Yamada M, Mendell J, Takakusa H, Shimizu T, Ando O. Pharmacokinetics, metabolism, and excretion of [14C]esaxerenone, a novel mineralocorticoid receptor blocker in humans. Drug Metab Dispos. 2019;47:340\u20139.","journal-title":"Drug Metab Dispos"},{"key":"1121_CR18","unstructured":"Ministry of Health, Labor and Welfare. Japanese dietary intake standard (2010 edition). Report on the study meeting of \u2018Japanese dietary intake standards\u2019 study report (May 2009). \nhttps:\/\/www.mhlw.go.jp\/shingi\/2009\/05\/s0529-4.html\n\n. Accessed 25 Sept 2018."},{"key":"1121_CR19","doi-asserted-by":"publisher","first-page":"e2877","DOI":"10.1097\/MD.0000000000002877","volume":"95","author":"Y Peng","year":"2016","unstructured":"Peng Y, Qi X, Guo X. Child\u2013Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Medicine (Baltimore). 2016;95:e2877.","journal-title":"Medicine (Baltimore)"},{"key":"1121_CR20","unstructured":"FDA. Guidance for Industry: Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. U.S. Department of Health and Human Services. Food and Drug Administration. May 2003. \nhttps:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm072123.pdf\n\n. Accessed 18 Aug 2018."},{"key":"1121_CR21","unstructured":"EMA. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. CPMP\/EWP\/2339\/02. February 2005. European Medicines Agency. Committee for Medicinal Products for Human Use. London: 2005. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003122.pdf\n\n. Accessed 18 Aug 2018."},{"key":"1121_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2165\/00002018-200528060-00005","volume":"28","author":"F Delc\u00f2","year":"2005","unstructured":"Delc\u00f2 F, Tchambaz L, Schlienger R, Drewe J, Kr\u00e4henb\u00fchl S. Dose adjustment in patients with liver disease. Drug Saf. 2005;28:529\u201345.","journal-title":"Drug Saf"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01121-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01121-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01121-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:49:30Z","timestamp":1604710170000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01121-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1121"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01121-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]},"assertion":[{"value":"23 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}